MAPT and Alzheimer disease: The development of tau-specific PET tracers is now gaining in interest since post-mortem studies have indicated that tau pathology seems to track cognitive deterioration better than amyloid-beta deposition, and has been observed in both AD and non-AD-related neurodegenerative diseases (i.e. primary tauopathies) [1].